Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia

Por Cantillon, Marc, Ings, Robert, Bhat, Laxminarayan
Publicado no Clin Transl Sci (2018)

Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients

Por Cantillon, Marc, Ings, Robert, Bhat, Laxminarayan
Publicado no Clin Transl Sci (2017)

A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder

Por Cantillon, Marc, Ings, Robert, Prakash, Arul, Bhat, Laxminarayan
Publicado no Eur J Drug Metab Pharmacokinet (2018)

Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease

Por Frank, Lori, Lenderking, William R, Howard, Kellee, Cantillon, Marc
Publicado em 2011

Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects

Por Mukai, Mayumi, Uchimura, Tatsuo, Zhang, Xiaoping, Greene, Douglas, Vergeire, Maria, Cantillon, Marc
Publicado no J Clin Pharmacol (2017)

Evaluation of the exposure equivalence of oral versus intravenous temozolomide

Por Diez, Blanca D., Statkevich, Paul, Zhu, Yali, Abutarif, Malaz A., Xuan, Fengjuan, Kantesaria, Bhavna, Cutler, David, Cantillon, Marc, Schwarz, Max, Pallotta, Maria Guadalupe, Ottaviano, Fabio H.
Publicado em 2009

Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criteria for Alzheimer’s disease

Por Jack, Clifford R, Barkhof, Frederik, Bernstein, Matt A, Cantillon, Marc, Cole, Patricia E, DeCarli, Charles, Dubois, Bruno, Duchesne, Simon, Fox, Nick C, Frisoni, Giovanni B, Hampel, Harald, Hill, Derek LG, Johnson, Keith, Mangin, Jean-François, Scheltens, Philip, Schwarz, Adam J, Sperling, Reisa, Suhy, Joyce, Thompson, Paul M, Weiner, Michael, Foster, Norman L
Publicado em 2011

Frontotemporal Degeneration, the Next Therapeutic Frontier: Molecules and Animal Models for FTD drug development (Part 1 of 2 articles)

Por Boxer, Adam L., Gold, Michael, Huey, Edward, Gao, Fen-Biao, Burton, Edward A., Chow, Tiffany, Kao, Aimee, Leavitt, Blair, Lamb, Bruce, Grether, Megan, Knopman, David, Cairns, Nigel J., Mackenzie, Ian R., Mitic, Laura, Roberson, Erik D., Van Kammen, Daniel, Cantillon, Marc, Zahs, Kathleen, Salloway, Stephen, Morris, John, Tong, Gary, Feldman, Howard, Fillit, Howard, Dickinson, Susan, Khachaturian, Zaven, Sutherland, Margaret, Farese, Robert, Miller, Bruce L., Cummings, Jeffrey
Publicado em 2012

The Advantages of FTD Drug Development (Part 2 of FTD: The Next Therapeutic Frontier)

Por Boxer, Adam L., Gold, Michael, Huey, Edward, Hu, William T., Rosen, Howard, Kramer, Joel, Gao, Fen-Biao, Burton, Edward A., Chow, Tiffany, Kao, Aimee, Leavitt, Blair, Lamb, Bruce, Grether, Megan, Knopman, David, Cairns, Nigel J., Mackenzie, Ian, Mitic, Laura, Roberson, Erik D., Van Kammen, Daniel, Cantillon, Marc, Zahs, Kathleen, Jackson, George, Salloway, Stephen, Morris, John, Tong, Gary, Feldman, Howard, Fillit, Howard, Dickinson, Susan, Khachaturian, Zaven, Sutherland, Margaret, Abushakra, Susan, Lewcock, Joseph, Farese, Robert, Kenet, Robert O., LaFerla, Frank, Perrin, Steve, Whitaker, Steve, Honig, Lawrence, Mesulam, Marsel, Boeve, Brad, Grossman, Murray, Miller, Bruce, Cummings, Jeffrey
Publicado em 2012